Kavita ici 2026
2026-01-05
excel: 25397
excel with dem: 20383
remove no baseline cre: 18319
remove missing esrd_kt!=0, eGFR_CRE_baseline <10 : 18157
remove missing last_cre_date< ICI_date:17937 (17752 with labs after ici date)
remove 216 placebo :17721
remove 3 death_date < ici_date(RPDR error): 17718
1year
| Characteristic | N = 9,1881 |
|---|---|
| age_ici | 66 (57, 73) |
| male | |
| 0 | 4,387 (48%) |
| 1 | 4,801 (52%) |
| Race | |
| Asian | 282 (3.1%) |
| Black | 264 (2.9%) |
| Other/Unknown | 388 (4.2%) |
| White | 8,254 (90%) |
| Ethnic_Group | |
| Hispanic | 175 (1.9%) |
| Non_hispanic | 8,459 (92%) |
| Other | 554 (6.0%) |
| ckd_incidence_1year | |
| 0 | 8,928 (97%) |
| 1 | 260 (2.8%) |
| ckd_progression_1year | |
| 0 | 8,884 (97%) |
| 1 | 304 (3.3%) |
| eskd_composite_1year | |
| 0 | 9,161 (100%) |
| 1 | 27 (0.3%) |
| ckd_composite_1year | |
| 0 | 8,863 (96%) |
| 1 | 325 (3.5%) |
| ckd_stage_1year | |
| 1 | 3,738 (41%) |
| 2 | 3,834 (42%) |
| 3 | 1,514 (16%) |
| 4 | 93 (1.0%) |
| 5 | 9 (<0.1%) |
| ckd_stage_baseline | |
| 1 | 4,230 (46%) |
| 2 | 3,718 (40%) |
| 3 | 1,173 (13%) |
| 4 | 65 (0.7%) |
| 5 | 2 (<0.1%) |
| dm | |
| 0 | 7,927 (86%) |
| 1 | 1,261 (14%) |
| htn | |
| 0 | 3,779 (41%) |
| 1 | 5,409 (59%) |
| cad | |
| 0 | 7,270 (79%) |
| 1 | 1,918 (21%) |
| ace_arb | |
| 0 | 5,071 (55%) |
| 1 | 4,117 (45%) |
| diu | |
| 0 | 4,339 (47%) |
| 1 | 4,849 (53%) |
| ppi | |
| 0 | 2,545 (28%) |
| 1 | 6,643 (72%) |
| steroids | |
| 0 | 2,454 (27%) |
| 1 | 6,734 (73%) |
| smoking | |
| 0 | 4,487 (49%) |
| 1 | 4,701 (51%) |
| Bevacizumab | |
| 0 | 8,598 (94%) |
| 1 | 590 (6.4%) |
| Cisplatin | |
| 0 | 7,969 (87%) |
| 1 | 1,219 (13%) |
| Carboplatin | |
| 0 | 6,323 (69%) |
| 1 | 2,865 (31%) |
| Pemetrexed | |
| 0 | 7,960 (87%) |
| 1 | 1,228 (13%) |
| Gemcitabine | |
| 0 | 8,048 (88%) |
| 1 | 1,140 (12%) |
| Cetuximab | |
| 0 | 8,982 (98%) |
| 1 | 206 (2.2%) |
| Trastuzumab | |
| 0 | 8,913 (97%) |
| 1 | 275 (3.0%) |
| VEGF_TKI | |
| 0 | 8,400 (91%) |
| 1 | 788 (8.6%) |
| ICI_Class | |
| PD1 | 6,242 (68%) |
| Combination | 1,169 (13%) |
| CTLA4 | 421 (4.6%) |
| PDL1 | 1,356 (15%) |
| nephrotoxic_chemo | |
| 0 | 4,784 (52%) |
| 1 | 4,404 (48%) |
| pre_CRE_180days | 0.86 (0.72, 1.04) |
| pre_HGB_180days | 12.70 (11.40, 13.90) |
| Missing | 8 |
| pre_ALB_180days | 4.10 (3.90, 4.40) |
| Missing | 27 |
| eGFR_CRE_baseline | 88 (71, 99) |
| 1 Median (Q1, Q3); n (%) | |
2year
| Characteristic | N = 5,8561 |
|---|---|
| age_ici | 65 (56, 73) |
| male | |
| 0 | 2,747 (47%) |
| 1 | 3,109 (53%) |
| Race | |
| Asian | 159 (2.7%) |
| Black | 148 (2.5%) |
| Other/Unknown | 234 (4.0%) |
| White | 5,315 (91%) |
| Ethnic_Group | |
| Hispanic | 95 (1.6%) |
| Non_hispanic | 5,392 (92%) |
| Other | 369 (6.3%) |
| ckd_incidence_2year | |
| 0 | 5,522 (94%) |
| 1 | 334 (5.7%) |
| ckd_progression_2year | |
| 0 | 5,464 (93%) |
| 1 | 392 (6.7%) |
| eskd_composite_2year | |
| 0 | 5,831 (100%) |
| 1 | 25 (0.4%) |
| ckd_composite_2year | |
| 0 | 5,449 (93%) |
| 1 | 407 (7.0%) |
| ckd_stage_1year | |
| 1 | 2,267 (39%) |
| 2 | 2,574 (44%) |
| 3 | 962 (16%) |
| 4 | 50 (0.9%) |
| 5 | 3 (<0.1%) |
| ckd_stage_2year | |
| 1 | 2,168 (37%) |
| 2 | 2,616 (45%) |
| 3 | 1,005 (17%) |
| 4 | 61 (1.0%) |
| 5 | 6 (0.1%) |
| ckd_stage_baseline | |
| 1 | 2,662 (45%) |
| 2 | 2,439 (42%) |
| 3 | 715 (12%) |
| 4 | 38 (0.6%) |
| 5 | 2 (<0.1%) |
| dm | |
| 0 | 5,093 (87%) |
| 1 | 763 (13%) |
| htn | |
| 0 | 2,442 (42%) |
| 1 | 3,414 (58%) |
| cad | |
| 0 | 4,677 (80%) |
| 1 | 1,179 (20%) |
| ace_arb | |
| 0 | 3,182 (54%) |
| 1 | 2,674 (46%) |
| diu | |
| 0 | 2,824 (48%) |
| 1 | 3,032 (52%) |
| ppi | |
| 0 | 1,616 (28%) |
| 1 | 4,240 (72%) |
| steroids | |
| 0 | 1,598 (27%) |
| 1 | 4,258 (73%) |
| smoking | |
| 0 | 2,868 (49%) |
| 1 | 2,988 (51%) |
| Bevacizumab | |
| 0 | 5,528 (94%) |
| 1 | 328 (5.6%) |
| Cisplatin | |
| 0 | 5,114 (87%) |
| 1 | 742 (13%) |
| Carboplatin | |
| 0 | 4,222 (72%) |
| 1 | 1,634 (28%) |
| Pemetrexed | |
| 0 | 5,103 (87%) |
| 1 | 753 (13%) |
| Gemcitabine | |
| 0 | 5,210 (89%) |
| 1 | 646 (11%) |
| Cetuximab | |
| 0 | 5,748 (98%) |
| 1 | 108 (1.8%) |
| Trastuzumab | |
| 0 | 5,696 (97%) |
| 1 | 160 (2.7%) |
| VEGF_TKI | |
| 0 | 5,336 (91%) |
| 1 | 520 (8.9%) |
| ICI_Class | |
| PD1 | 3,925 (67%) |
| Combination | 797 (14%) |
| CTLA4 | 319 (5.4%) |
| PDL1 | 815 (14%) |
| nephrotoxic_chemo | |
| 0 | 3,328 (57%) |
| 1 | 2,528 (43%) |
| pre_CRE_180days | 0.86 (0.72, 1.04) |
| pre_HGB_180days | 12.80 (11.50, 14.00) |
| Missing | 6 |
| pre_ALB_180days | 4.20 (3.90, 4.40) |
| Missing | 18 |
| eGFR_CRE_baseline | 88 (72, 99) |
| 1 Median (Q1, Q3); n (%) | |
3year
| Characteristic | N = 3,6551 |
|---|---|
| age_ici | 65 (56, 72) |
| male | |
| 0 | 1,674 (46%) |
| 1 | 1,981 (54%) |
| Race | |
| Asian | 83 (2.3%) |
| Black | 78 (2.1%) |
| Other/Unknown | 142 (3.9%) |
| White | 3,352 (92%) |
| Ethnic_Group | |
| Hispanic | 55 (1.5%) |
| Non_hispanic | 3,374 (92%) |
| Other | 226 (6.2%) |
| ckd_incidence_3year | |
| 0 | 3,374 (92%) |
| 1 | 281 (7.7%) |
| ckd_progression_3year | |
| 0 | 3,318 (91%) |
| 1 | 337 (9.2%) |
| eskd_composite_3year | |
| 0 | 3,638 (100%) |
| 1 | 17 (0.5%) |
| ckd_composite_3year | |
| 0 | 3,309 (91%) |
| 1 | 346 (9.5%) |
| ckd_stage_1year | |
| 1 | 1,423 (39%) |
| 2 | 1,625 (44%) |
| 3 | 577 (16%) |
| 4 | 28 (0.8%) |
| 5 | 2 (<0.1%) |
| ckd_stage_2year | |
| 1 | 1,341 (37%) |
| 2 | 1,686 (46%) |
| 3 | 600 (16%) |
| 4 | 27 (0.7%) |
| 5 | 1 (<0.1%) |
| ckd_stage_3year | |
| 1 | 1,289 (35%) |
| 2 | 1,711 (47%) |
| 3 | 606 (17%) |
| 4 | 42 (1.1%) |
| 5 | 7 (0.2%) |
| ckd_stage_baseline | |
| 1 | 1,678 (46%) |
| 2 | 1,525 (42%) |
| 3 | 435 (12%) |
| 4 | 16 (0.4%) |
| 5 | 1 (<0.1%) |
| dm | |
| 0 | 3,209 (88%) |
| 1 | 446 (12%) |
| htn | |
| 0 | 1,510 (41%) |
| 1 | 2,145 (59%) |
| cad | |
| 0 | 2,947 (81%) |
| 1 | 708 (19%) |
| ace_arb | |
| 0 | 1,939 (53%) |
| 1 | 1,716 (47%) |
| diu | |
| 0 | 1,735 (47%) |
| 1 | 1,920 (53%) |
| ppi | |
| 0 | 983 (27%) |
| 1 | 2,672 (73%) |
| steroids | |
| 0 | 998 (27%) |
| 1 | 2,657 (73%) |
| smoking | |
| 0 | 1,757 (48%) |
| 1 | 1,898 (52%) |
| Bevacizumab | |
| 0 | 3,471 (95%) |
| 1 | 184 (5.0%) |
| Cisplatin | |
| 0 | 3,222 (88%) |
| 1 | 433 (12%) |
| Carboplatin | |
| 0 | 2,748 (75%) |
| 1 | 907 (25%) |
| Pemetrexed | |
| 0 | 3,197 (87%) |
| 1 | 458 (13%) |
| Gemcitabine | |
| 0 | 3,304 (90%) |
| 1 | 351 (9.6%) |
| Cetuximab | |
| 0 | 3,598 (98%) |
| 1 | 57 (1.6%) |
| Trastuzumab | |
| 0 | 3,571 (98%) |
| 1 | 84 (2.3%) |
| VEGF_TKI | |
| 0 | 3,341 (91%) |
| 1 | 314 (8.6%) |
| ICI_Class | |
| PD1 | 2,443 (67%) |
| Combination | 504 (14%) |
| CTLA4 | 221 (6.0%) |
| PDL1 | 487 (13%) |
| nephrotoxic_chemo | |
| 0 | 2,232 (61%) |
| 1 | 1,423 (39%) |
| pre_CRE_180days | 0.87 (0.73, 1.04) |
| pre_HGB_180days | 13.00 (11.70, 14.10) |
| Missing | 5 |
| pre_ALB_180days | 4.20 (3.90, 4.40) |
| Missing | 13 |
| eGFR_CRE_baseline | 88 (72, 99) |
| 1 Median (Q1, Q3); n (%) | |
4year
| Characteristic | N = 2,4361 |
|---|---|
| age_ici | 64 (55, 71) |
| male | |
| 0 | 1,112 (46%) |
| 1 | 1,324 (54%) |
| Race | |
| Asian | 51 (2.1%) |
| Black | 43 (1.8%) |
| Other/Unknown | 90 (3.7%) |
| White | 2,252 (92%) |
| Ethnic_Group | |
| Hispanic | 35 (1.4%) |
| Non_hispanic | 2,239 (92%) |
| Other | 162 (6.7%) |
| ckd_incidence_4year | |
| 0 | 2,215 (91%) |
| 1 | 221 (9.1%) |
| ckd_progression_4year | |
| 0 | 2,172 (89%) |
| 1 | 264 (11%) |
| eskd_composite_4year | |
| 0 | 2,423 (99%) |
| 1 | 13 (0.5%) |
| ckd_composite_4year | |
| 0 | 2,164 (89%) |
| 1 | 272 (11%) |
| ckd_stage_1year | |
| 1 | 946 (39%) |
| 2 | 1,109 (46%) |
| 3 | 359 (15%) |
| 4 | 20 (0.8%) |
| 5 | 2 (<0.1%) |
| ckd_stage_2year | |
| 1 | 906 (37%) |
| 2 | 1,138 (47%) |
| 3 | 373 (15%) |
| 4 | 18 (0.7%) |
| 5 | 1 (<0.1%) |
| ckd_stage_3year | |
| 1 | 846 (35%) |
| 2 | 1,181 (48%) |
| 3 | 387 (16%) |
| 4 | 19 (0.8%) |
| 5 | 3 (0.1%) |
| ckd_stage_4year | |
| 1 | 878 (36%) |
| 2 | 1,112 (46%) |
| 3 | 420 (17%) |
| 4 | 24 (1.0%) |
| 5 | 2 (<0.1%) |
| ckd_stage_baseline | |
| 1 | 1,144 (47%) |
| 2 | 1,005 (41%) |
| 3 | 278 (11%) |
| 4 | 8 (0.3%) |
| 5 | 1 (<0.1%) |
| dm | |
| 0 | 2,155 (88%) |
| 1 | 281 (12%) |
| htn | |
| 0 | 991 (41%) |
| 1 | 1,445 (59%) |
| cad | |
| 0 | 1,962 (81%) |
| 1 | 474 (19%) |
| ace_arb | |
| 0 | 1,280 (53%) |
| 1 | 1,156 (47%) |
| diu | |
| 0 | 1,163 (48%) |
| 1 | 1,273 (52%) |
| ppi | |
| 0 | 608 (25%) |
| 1 | 1,828 (75%) |
| steroids | |
| 0 | 687 (28%) |
| 1 | 1,749 (72%) |
| smoking | |
| 0 | 1,172 (48%) |
| 1 | 1,264 (52%) |
| Bevacizumab | |
| 0 | 2,322 (95%) |
| 1 | 114 (4.7%) |
| Cisplatin | |
| 0 | 2,167 (89%) |
| 1 | 269 (11%) |
| Carboplatin | |
| 0 | 1,899 (78%) |
| 1 | 537 (22%) |
| Pemetrexed | |
| 0 | 2,161 (89%) |
| 1 | 275 (11%) |
| Gemcitabine | |
| 0 | 2,222 (91%) |
| 1 | 214 (8.8%) |
| Cetuximab | |
| 0 | 2,406 (99%) |
| 1 | 30 (1.2%) |
| Trastuzumab | |
| 0 | 2,383 (98%) |
| 1 | 53 (2.2%) |
| VEGF_TKI | |
| 0 | 2,247 (92%) |
| 1 | 189 (7.8%) |
| ICI_Class | |
| PD1 | 1,626 (67%) |
| Combination | 329 (14%) |
| CTLA4 | 158 (6.5%) |
| PDL1 | 323 (13%) |
| nephrotoxic_chemo | |
| 0 | 1,572 (65%) |
| 1 | 864 (35%) |
| pre_CRE_180days | 0.87 (0.73, 1.04) |
| pre_HGB_180days | 13.10 (11.80, 14.20) |
| Missing | 1 |
| pre_ALB_180days | 4.20 (3.90, 4.40) |
| Missing | 7 |
| eGFR_CRE_baseline | 89 (73, 100) |
| 1 Median (Q1, Q3); n (%) | |
5year
| Characteristic | N = 1,6611 |
|---|---|
| age_ici | 63 (54, 70) |
| male | |
| 0 | 757 (46%) |
| 1 | 904 (54%) |
| Race | |
| Asian | 37 (2.2%) |
| Black | 25 (1.5%) |
| Other/Unknown | 58 (3.5%) |
| White | 1,541 (93%) |
| Ethnic_Group | |
| Hispanic | 25 (1.5%) |
| Non_hispanic | 1,520 (92%) |
| Other | 116 (7.0%) |
| ckd_incidence_5year | |
| 0 | 1,489 (90%) |
| 1 | 172 (10%) |
| ckd_progression_5year | |
| 0 | 1,450 (87%) |
| 1 | 211 (13%) |
| eskd_composite_5year | |
| 0 | 1,649 (99%) |
| 1 | 12 (0.7%) |
| ckd_composite_5year | |
| 0 | 1,442 (87%) |
| 1 | 219 (13%) |
| ckd_stage_1year | |
| 1 | 662 (40%) |
| 2 | 753 (45%) |
| 3 | 235 (14%) |
| 4 | 10 (0.6%) |
| 5 | 1 (<0.1%) |
| ckd_stage_2year | |
| 1 | 620 (37%) |
| 2 | 793 (48%) |
| 3 | 238 (14%) |
| 4 | 9 (0.5%) |
| 5 | 1 (<0.1%) |
| ckd_stage_3year | |
| 1 | 574 (35%) |
| 2 | 824 (50%) |
| 3 | 255 (15%) |
| 4 | 5 (0.3%) |
| 5 | 3 (0.2%) |
| ckd_stage_4year | |
| 1 | 600 (36%) |
| 2 | 778 (47%) |
| 3 | 270 (16%) |
| 4 | 11 (0.7%) |
| 5 | 2 (0.1%) |
| ckd_stage_5year | |
| 1 | 611 (37%) |
| 2 | 767 (46%) |
| 3 | 263 (16%) |
| 4 | 17 (1.0%) |
| 5 | 3 (0.2%) |
| ckd_stage_baseline | |
| 1 | 801 (48%) |
| 2 | 680 (41%) |
| 3 | 174 (10%) |
| 4 | 6 (0.4%) |
| 5 | 0 (0%) |
| dm | |
| 0 | 1,484 (89%) |
| 1 | 177 (11%) |
| htn | |
| 0 | 681 (41%) |
| 1 | 980 (59%) |
| cad | |
| 0 | 1,356 (82%) |
| 1 | 305 (18%) |
| ace_arb | |
| 0 | 883 (53%) |
| 1 | 778 (47%) |
| diu | |
| 0 | 787 (47%) |
| 1 | 874 (53%) |
| ppi | |
| 0 | 402 (24%) |
| 1 | 1,259 (76%) |
| steroids | |
| 0 | 477 (29%) |
| 1 | 1,184 (71%) |
| smoking | |
| 0 | 809 (49%) |
| 1 | 852 (51%) |
| Bevacizumab | |
| 0 | 1,586 (95%) |
| 1 | 75 (4.5%) |
| Cisplatin | |
| 0 | 1,483 (89%) |
| 1 | 178 (11%) |
| Carboplatin | |
| 0 | 1,318 (79%) |
| 1 | 343 (21%) |
| Pemetrexed | |
| 0 | 1,491 (90%) |
| 1 | 170 (10%) |
| Gemcitabine | |
| 0 | 1,523 (92%) |
| 1 | 138 (8.3%) |
| Cetuximab | |
| 0 | 1,642 (99%) |
| 1 | 19 (1.1%) |
| Trastuzumab | |
| 0 | 1,627 (98%) |
| 1 | 34 (2.0%) |
| VEGF_TKI | |
| 0 | 1,554 (94%) |
| 1 | 107 (6.4%) |
| ICI_Class | |
| PD1 | 1,131 (68%) |
| Combination | 205 (12%) |
| CTLA4 | 119 (7.2%) |
| PDL1 | 206 (12%) |
| nephrotoxic_chemo | |
| 0 | 1,105 (67%) |
| 1 | 556 (33%) |
| pre_CRE_180days | 0.87 (0.72, 1.03) |
| pre_HGB_180days | 13.20 (11.90, 14.20) |
| Missing | 1 |
| pre_ALB_180days | 4.20 (3.90, 4.40) |
| Missing | 6 |
| eGFR_CRE_baseline | 89 (74, 100) |
| 1 Median (Q1, Q3); n (%) | |
6year
| Characteristic | N = 1,0791 |
|---|---|
| age_ici | 62 (53, 69) |
| male | |
| 0 | 504 (47%) |
| 1 | 575 (53%) |
| Race | |
| Asian | 18 (1.7%) |
| Black | 23 (2.1%) |
| Other/Unknown | 38 (3.5%) |
| White | 1,000 (93%) |
| Ethnic_Group | |
| Hispanic | 14 (1.3%) |
| Non_hispanic | 982 (91%) |
| Other | 83 (7.7%) |
| ckd_incidence_6year | |
| 0 | 958 (89%) |
| 1 | 121 (11%) |
| ckd_progression_6year | |
| 0 | 929 (86%) |
| 1 | 150 (14%) |
| eskd_composite_6year | |
| 0 | 1,070 (99%) |
| 1 | 9 (0.8%) |
| ckd_composite_6year | 155 (14%) |
| ckd_stage_1year | |
| 1 | 459 (43%) |
| 2 | 481 (45%) |
| 3 | 134 (12%) |
| 4 | 4 (0.4%) |
| 5 | 1 (<0.1%) |
| ckd_stage_2year | |
| 1 | 413 (38%) |
| 2 | 524 (49%) |
| 3 | 139 (13%) |
| 4 | 2 (0.2%) |
| 5 | 1 (<0.1%) |
| ckd_stage_3year | |
| 1 | 378 (35%) |
| 2 | 543 (50%) |
| 3 | 154 (14%) |
| 4 | 3 (0.3%) |
| 5 | 1 (<0.1%) |
| ckd_stage_4year | |
| 1 | 403 (37%) |
| 2 | 511 (47%) |
| 3 | 160 (15%) |
| 4 | 4 (0.4%) |
| 5 | 1 (<0.1%) |
| ckd_stage_5year | |
| 1 | 416 (39%) |
| 2 | 500 (46%) |
| 3 | 152 (14%) |
| 4 | 9 (0.8%) |
| 5 | 2 (0.2%) |
| ckd_stage_6year | |
| 1 | 402 (37%) |
| 2 | 503 (47%) |
| 3 | 159 (15%) |
| 4 | 12 (1.1%) |
| 5 | 3 (0.3%) |
| ckd_stage_baseline | |
| 1 | 539 (50%) |
| 2 | 429 (40%) |
| 3 | 109 (10%) |
| 4 | 2 (0.2%) |
| 5 | 0 (0%) |
| dm | |
| 0 | 965 (89%) |
| 1 | 114 (11%) |
| htn | |
| 0 | 436 (40%) |
| 1 | 643 (60%) |
| cad | |
| 0 | 892 (83%) |
| 1 | 187 (17%) |
| ace_arb | |
| 0 | 581 (54%) |
| 1 | 498 (46%) |
| diu | |
| 0 | 527 (49%) |
| 1 | 552 (51%) |
| ppi | |
| 0 | 238 (22%) |
| 1 | 841 (78%) |
| steroids | |
| 0 | 305 (28%) |
| 1 | 774 (72%) |
| smoking | |
| 0 | 527 (49%) |
| 1 | 552 (51%) |
| Bevacizumab | |
| 0 | 1,032 (96%) |
| 1 | 47 (4.4%) |
| Cisplatin | |
| 0 | 962 (89%) |
| 1 | 117 (11%) |
| Carboplatin | |
| 0 | 870 (81%) |
| 1 | 209 (19%) |
| Pemetrexed | |
| 0 | 976 (90%) |
| 1 | 103 (9.5%) |
| Gemcitabine | |
| 0 | 1,002 (93%) |
| 1 | 77 (7.1%) |
| Cetuximab | |
| 0 | 1,069 (99%) |
| 1 | 10 (0.9%) |
| Trastuzumab | |
| 0 | 1,057 (98%) |
| 1 | 22 (2.0%) |
| VEGF_TKI | |
| 0 | 1,015 (94%) |
| 1 | 64 (5.9%) |
| ICI_Class | |
| PD1 | 721 (67%) |
| Combination | 120 (11%) |
| CTLA4 | 104 (9.6%) |
| PDL1 | 134 (12%) |
| nephrotoxic_chemo | |
| 0 | 742 (69%) |
| 1 | 337 (31%) |
| pre_CRE_180days | 0.86 (0.72, 1.03) |
| pre_HGB_180days | 13.30 (12.10, 14.20) |
| pre_ALB_180days | 4.20 (3.90, 4.40) |
| Missing | 3 |
| eGFR_CRE_baseline | 90 (75, 101) |
| 1 Median (Q1, Q3); n (%) | |
7year
| Characteristic | N = 6601 |
|---|---|
| age_ici | 61 (53, 69) |
| male | |
| 0 | 299 (45%) |
| 1 | 361 (55%) |
| Race | |
| Asian | 9 (1.4%) |
| Black | 15 (2.3%) |
| Other/Unknown | 24 (3.6%) |
| White | 612 (93%) |
| Ethnic_Group | |
| Hispanic | 10 (1.5%) |
| Non_hispanic | 598 (91%) |
| Other | 52 (7.9%) |
| ckd_incidence_7year | |
| 0 | 577 (87%) |
| 1 | 83 (13%) |
| ckd_progression_7year | |
| 0 | 562 (85%) |
| 1 | 98 (15%) |
| eskd_composite_7year | |
| 0 | 651 (99%) |
| 1 | 9 (1.4%) |
| ckd_composite_7year | 101 (15%) |
| ckd_stage_1year | |
| 1 | 289 (44%) |
| 2 | 292 (44%) |
| 3 | 75 (11%) |
| 4 | 3 (0.5%) |
| 5 | 1 (0.2%) |
| ckd_stage_2year | |
| 1 | 267 (40%) |
| 2 | 309 (47%) |
| 3 | 82 (12%) |
| 4 | 1 (0.2%) |
| 5 | 1 (0.2%) |
| ckd_stage_3year | |
| 1 | 244 (37%) |
| 2 | 322 (49%) |
| 3 | 92 (14%) |
| 4 | 1 (0.2%) |
| 5 | 1 (0.2%) |
| ckd_stage_4year | |
| 1 | 252 (38%) |
| 2 | 307 (47%) |
| 3 | 96 (15%) |
| 4 | 4 (0.6%) |
| 5 | 1 (0.2%) |
| ckd_stage_5year | |
| 1 | 262 (40%) |
| 2 | 300 (45%) |
| 3 | 91 (14%) |
| 4 | 5 (0.8%) |
| 5 | 2 (0.3%) |
| ckd_stage_6year | |
| 1 | 255 (39%) |
| 2 | 305 (46%) |
| 3 | 90 (14%) |
| 4 | 8 (1.2%) |
| 5 | 2 (0.3%) |
| ckd_stage_7year | |
| 1 | 242 (37%) |
| 2 | 313 (47%) |
| 3 | 91 (14%) |
| 4 | 10 (1.5%) |
| 5 | 4 (0.6%) |
| ckd_stage_baseline | |
| 1 | 340 (52%) |
| 2 | 255 (39%) |
| 3 | 63 (9.5%) |
| 4 | 2 (0.3%) |
| 5 | 0 (0%) |
| dm | |
| 0 | 584 (88%) |
| 1 | 76 (12%) |
| htn | |
| 0 | 255 (39%) |
| 1 | 405 (61%) |
| cad | |
| 0 | 557 (84%) |
| 1 | 103 (16%) |
| ace_arb | |
| 0 | 355 (54%) |
| 1 | 305 (46%) |
| diu | |
| 0 | 317 (48%) |
| 1 | 343 (52%) |
| ppi | |
| 0 | 133 (20%) |
| 1 | 527 (80%) |
| steroids | |
| 0 | 194 (29%) |
| 1 | 466 (71%) |
| smoking | |
| 0 | 324 (49%) |
| 1 | 336 (51%) |
| Bevacizumab | |
| 0 | 633 (96%) |
| 1 | 27 (4.1%) |
| Cisplatin | |
| 0 | 611 (93%) |
| 1 | 49 (7.4%) |
| Carboplatin | |
| 0 | 555 (84%) |
| 1 | 105 (16%) |
| Pemetrexed | |
| 0 | 605 (92%) |
| 1 | 55 (8.3%) |
| Gemcitabine | |
| 0 | 623 (94%) |
| 1 | 37 (5.6%) |
| Cetuximab | |
| 0 | 655 (99%) |
| 1 | 5 (0.8%) |
| Trastuzumab | |
| 0 | 647 (98%) |
| 1 | 13 (2.0%) |
| VEGF_TKI | |
| 0 | 622 (94%) |
| 1 | 38 (5.8%) |
| ICI_Class | |
| PD1 | 425 (64%) |
| Combination | 81 (12%) |
| CTLA4 | 84 (13%) |
| PDL1 | 70 (11%) |
| nephrotoxic_chemo | |
| 0 | 490 (74%) |
| 1 | 170 (26%) |
| pre_CRE_180days | 0.86 (0.73, 1.04) |
| pre_HGB_180days | 13.20 (12.00, 14.15) |
| pre_ALB_180days | 4.20 (3.90, 4.40) |
| Missing | 3 |
| eGFR_CRE_baseline | 91 (74, 102) |
| 1 Median (Q1, Q3); n (%) | |
8year
| Characteristic | N = 3871 |
|---|---|
| age_ici | 62 (52, 69) |
| male | |
| 0 | 160 (41%) |
| 1 | 227 (59%) |
| Race | |
| Asian | 5 (1.3%) |
| Black | 7 (1.8%) |
| Other/Unknown | 8 (2.1%) |
| White | 367 (95%) |
| Ethnic_Group | |
| Hispanic | 6 (1.6%) |
| Non_hispanic | 345 (89%) |
| Other | 36 (9.3%) |
| ckd_incidence_8year | |
| 0 | 332 (86%) |
| 1 | 55 (14%) |
| ckd_progression_8year | |
| 0 | 325 (84%) |
| 1 | 62 (16%) |
| eskd_composite_8year | |
| 0 | 383 (99%) |
| 1 | 4 (1.0%) |
| ckd_composite_8year | 64 (17%) |
| ckd_stage_1year | |
| 1 | 169 (44%) |
| 2 | 176 (45%) |
| 3 | 42 (11%) |
| 4 | 0 (0%) |
| 5 | 0 (0%) |
| ckd_stage_2year | |
| 1 | 156 (40%) |
| 2 | 184 (48%) |
| 3 | 47 (12%) |
| 4 | 0 (0%) |
| 5 | 0 (0%) |
| ckd_stage_3year | |
| 1 | 145 (37%) |
| 2 | 192 (50%) |
| 3 | 50 (13%) |
| 4 | 0 (0%) |
| 5 | 0 (0%) |
| ckd_stage_4year | |
| 1 | 151 (39%) |
| 2 | 181 (47%) |
| 3 | 54 (14%) |
| 4 | 1 (0.3%) |
| 5 | 0 (0%) |
| ckd_stage_5year | |
| 1 | 153 (40%) |
| 2 | 176 (45%) |
| 3 | 56 (14%) |
| 4 | 2 (0.5%) |
| 5 | 0 (0%) |
| ckd_stage_6year | |
| 1 | 150 (39%) |
| 2 | 178 (46%) |
| 3 | 56 (14%) |
| 4 | 3 (0.8%) |
| 5 | 0 (0%) |
| ckd_stage_7year | |
| 1 | 149 (39%) |
| 2 | 180 (47%) |
| 3 | 53 (14%) |
| 4 | 5 (1.3%) |
| 5 | 0 (0%) |
| ckd_stage_8year | |
| 1 | 145 (37%) |
| 2 | 180 (47%) |
| 3 | 56 (14%) |
| 4 | 6 (1.6%) |
| 5 | 0 (0%) |
| ckd_stage_baseline | |
| 1 | 201 (52%) |
| 2 | 149 (39%) |
| 3 | 37 (9.6%) |
| 4 | 0 (0%) |
| 5 | 0 (0%) |
| dm | |
| 0 | 347 (90%) |
| 1 | 40 (10%) |
| htn | |
| 0 | 150 (39%) |
| 1 | 237 (61%) |
| cad | |
| 0 | 329 (85%) |
| 1 | 58 (15%) |
| ace_arb | |
| 0 | 207 (53%) |
| 1 | 180 (47%) |
| diu | |
| 0 | 189 (49%) |
| 1 | 198 (51%) |
| ppi | |
| 0 | 81 (21%) |
| 1 | 306 (79%) |
| steroids | |
| 0 | 136 (35%) |
| 1 | 251 (65%) |
| smoking | |
| 0 | 203 (52%) |
| 1 | 184 (48%) |
| Bevacizumab | |
| 0 | 374 (97%) |
| 1 | 13 (3.4%) |
| Cisplatin | |
| 0 | 364 (94%) |
| 1 | 23 (5.9%) |
| Carboplatin | |
| 0 | 338 (87%) |
| 1 | 49 (13%) |
| Pemetrexed | |
| 0 | 363 (94%) |
| 1 | 24 (6.2%) |
| Gemcitabine | |
| 0 | 371 (96%) |
| 1 | 16 (4.1%) |
| Cetuximab | |
| 0 | 384 (99%) |
| 1 | 3 (0.8%) |
| Trastuzumab | |
| 0 | 382 (99%) |
| 1 | 5 (1.3%) |
| VEGF_TKI | |
| 0 | 368 (95%) |
| 1 | 19 (4.9%) |
| ICI_Class | |
| PD1 | 216 (56%) |
| Combination | 60 (16%) |
| CTLA4 | 70 (18%) |
| PDL1 | 41 (11%) |
| nephrotoxic_chemo | |
| 0 | 307 (79%) |
| 1 | 80 (21%) |
| pre_CRE_180days | 0.87 (0.74, 1.03) |
| pre_HGB_180days | 13.20 (11.90, 14.20) |
| pre_ALB_180days | 4.20 (4.00, 4.40) |
| Missing | 2 |
| eGFR_CRE_baseline | 91 (75, 101) |
| 1 Median (Q1, Q3); n (%) | |
9year
| Characteristic | N = 2041 |
|---|---|
| age_ici | 60 (53, 68) |
| male | |
| 0 | 90 (44%) |
| 1 | 114 (56%) |
| Race | |
| Asian | 2 (1.0%) |
| Black | 2 (1.0%) |
| Other/Unknown | 3 (1.5%) |
| White | 197 (97%) |
| Ethnic_Group | |
| Hispanic | 1 (0.5%) |
| Non_hispanic | 186 (91%) |
| Other | 17 (8.3%) |
| ckd_incidence_9year | |
| 0 | 178 (87%) |
| 1 | 26 (13%) |
| ckd_progression_9year | |
| 0 | 175 (86%) |
| 1 | 29 (14%) |
| eskd_composite_9year | |
| 0 | 203 (100%) |
| 1 | 1 (0.5%) |
| ckd_composite_9year | 29 (14%) |
| ckd_stage_1year | |
| 1 | 90 (44%) |
| 2 | 96 (47%) |
| 3 | 18 (8.8%) |
| 4 | 0 (0%) |
| 5 | 0 (0%) |
| ckd_stage_2year | |
| 1 | 85 (42%) |
| 2 | 100 (49%) |
| 3 | 19 (9.3%) |
| 4 | 0 (0%) |
| 5 | 0 (0%) |
| ckd_stage_3year | |
| 1 | 79 (39%) |
| 2 | 105 (51%) |
| 3 | 20 (9.8%) |
| 4 | 0 (0%) |
| 5 | 0 (0%) |
| ckd_stage_4year | |
| 1 | 88 (43%) |
| 2 | 92 (45%) |
| 3 | 24 (12%) |
| 4 | 0 (0%) |
| 5 | 0 (0%) |
| ckd_stage_5year | |
| 1 | 87 (43%) |
| 2 | 89 (44%) |
| 3 | 28 (14%) |
| 4 | 0 (0%) |
| 5 | 0 (0%) |
| ckd_stage_6year | |
| 1 | 81 (40%) |
| 2 | 93 (46%) |
| 3 | 30 (15%) |
| 4 | 0 (0%) |
| 5 | 0 (0%) |
| ckd_stage_7year | |
| 1 | 88 (43%) |
| 2 | 87 (43%) |
| 3 | 29 (14%) |
| 4 | 0 (0%) |
| 5 | 0 (0%) |
| ckd_stage_8year | |
| 1 | 87 (43%) |
| 2 | 87 (43%) |
| 3 | 29 (14%) |
| 4 | 1 (0.5%) |
| 5 | 0 (0%) |
| ckd_stage_9year | |
| 1 | 89 (44%) |
| 2 | 81 (40%) |
| 3 | 34 (17%) |
| 4 | 0 (0%) |
| 5 | 0 (0%) |
| ckd_stage_baseline | |
| 1 | 104 (51%) |
| 2 | 83 (41%) |
| 3 | 17 (8.3%) |
| 4 | 0 (0%) |
| 5 | 0 (0%) |
| dm | |
| 0 | 187 (92%) |
| 1 | 17 (8.3%) |
| htn | |
| 0 | 72 (35%) |
| 1 | 132 (65%) |
| cad | |
| 0 | 183 (90%) |
| 1 | 21 (10%) |
| ace_arb | |
| 0 | 116 (57%) |
| 1 | 88 (43%) |
| diu | |
| 0 | 101 (50%) |
| 1 | 103 (50%) |
| ppi | |
| 0 | 40 (20%) |
| 1 | 164 (80%) |
| steroids | |
| 0 | 87 (43%) |
| 1 | 117 (57%) |
| smoking | |
| 0 | 109 (53%) |
| 1 | 95 (47%) |
| Bevacizumab | |
| 0 | 196 (96%) |
| 1 | 8 (3.9%) |
| Cisplatin | |
| 0 | 195 (96%) |
| 1 | 9 (4.4%) |
| Carboplatin | |
| 0 | 181 (89%) |
| 1 | 23 (11%) |
| Pemetrexed | |
| 0 | 193 (95%) |
| 1 | 11 (5.4%) |
| Gemcitabine | |
| 0 | 197 (97%) |
| 1 | 7 (3.4%) |
| Cetuximab | |
| 0 | 202 (99%) |
| 1 | 2 (1.0%) |
| Trastuzumab | |
| 0 | 201 (99%) |
| 1 | 3 (1.5%) |
| VEGF_TKI | |
| 0 | 195 (96%) |
| 1 | 9 (4.4%) |
| ICI_Class | |
| PD1 | 95 (47%) |
| Combination | 36 (18%) |
| CTLA4 | 57 (28%) |
| PDL1 | 16 (7.8%) |
| nephrotoxic_chemo | |
| 0 | 165 (81%) |
| 1 | 39 (19%) |
| pre_CRE_180days | 0.87 (0.76, 1.04) |
| pre_HGB_180days | 13.40 (11.95, 14.30) |
| pre_ALB_180days | 4.30 (4.10, 4.50) |
| eGFR_CRE_baseline | 91 (75, 102) |
| 1 Median (Q1, Q3); n (%) | |
10year
| Characteristic | N = 731 |
|---|---|
| age_ici | 60 (51, 67) |
| male | |
| 0 | 35 (48%) |
| 1 | 38 (52%) |
| Race | |
| Asian | 0 (0%) |
| Black | 0 (0%) |
| Other/Unknown | 0 (0%) |
| White | 73 (100%) |
| Ethnic_Group | |
| Hispanic | 0 (0%) |
| Non_hispanic | 69 (95%) |
| Other | 4 (5.5%) |
| ckd_incidence_10year | |
| 0 | 64 (88%) |
| 1 | 9 (12%) |
| ckd_progression_10year | |
| 0 | 62 (85%) |
| 1 | 11 (15%) |
| eskd_composite_10year | |
| 0 | 72 (99%) |
| 1 | 1 (1.4%) |
| ckd_composite_10year | 11 (15%) |
| ckd_stage_1year | |
| 1 | 33 (45%) |
| 2 | 30 (41%) |
| 3 | 10 (14%) |
| 4 | 0 (0%) |
| 5 | 0 (0%) |
| ckd_stage_2year | |
| 1 | 32 (44%) |
| 2 | 32 (44%) |
| 3 | 9 (12%) |
| 4 | 0 (0%) |
| 5 | 0 (0%) |
| ckd_stage_3year | |
| 1 | 31 (42%) |
| 2 | 32 (44%) |
| 3 | 10 (14%) |
| 4 | 0 (0%) |
| 5 | 0 (0%) |
| ckd_stage_4year | |
| 1 | 31 (42%) |
| 2 | 30 (41%) |
| 3 | 12 (16%) |
| 4 | 0 (0%) |
| 5 | 0 (0%) |
| ckd_stage_5year | |
| 1 | 31 (42%) |
| 2 | 31 (42%) |
| 3 | 11 (15%) |
| 4 | 0 (0%) |
| 5 | 0 (0%) |
| ckd_stage_6year | |
| 1 | 28 (38%) |
| 2 | 34 (47%) |
| 3 | 11 (15%) |
| 4 | 0 (0%) |
| 5 | 0 (0%) |
| ckd_stage_7year | |
| 1 | 28 (38%) |
| 2 | 33 (45%) |
| 3 | 12 (16%) |
| 4 | 0 (0%) |
| 5 | 0 (0%) |
| ckd_stage_8year | |
| 1 | 27 (37%) |
| 2 | 33 (45%) |
| 3 | 12 (16%) |
| 4 | 1 (1.4%) |
| 5 | 0 (0%) |
| ckd_stage_9year | |
| 1 | 30 (41%) |
| 2 | 30 (41%) |
| 3 | 13 (18%) |
| 4 | 0 (0%) |
| 5 | 0 (0%) |
| ckd_stage_10year | |
| 1 | 28 (38%) |
| 2 | 33 (45%) |
| 3 | 9 (12%) |
| 4 | 3 (4.1%) |
| 5 | 0 (0%) |
| ckd_stage_baseline | |
| 1 | 39 (53%) |
| 2 | 25 (34%) |
| 3 | 9 (12%) |
| 4 | 0 (0%) |
| 5 | 0 (0%) |
| dm | |
| 0 | 67 (92%) |
| 1 | 6 (8.2%) |
| htn | |
| 0 | 26 (36%) |
| 1 | 47 (64%) |
| cad | |
| 0 | 66 (90%) |
| 1 | 7 (9.6%) |
| ace_arb | |
| 0 | 38 (52%) |
| 1 | 35 (48%) |
| diu | |
| 0 | 35 (48%) |
| 1 | 38 (52%) |
| ppi | |
| 0 | 15 (21%) |
| 1 | 58 (79%) |
| steroids | |
| 0 | 40 (55%) |
| 1 | 33 (45%) |
| smoking | |
| 0 | 33 (45%) |
| 1 | 40 (55%) |
| Bevacizumab | |
| 0 | 70 (96%) |
| 1 | 3 (4.1%) |
| Cisplatin | |
| 0 | 71 (97%) |
| 1 | 2 (2.7%) |
| Carboplatin | |
| 0 | 68 (93%) |
| 1 | 5 (6.8%) |
| Pemetrexed | |
| 0 | 69 (95%) |
| 1 | 4 (5.5%) |
| Gemcitabine | |
| 0 | 72 (99%) |
| 1 | 1 (1.4%) |
| Cetuximab | |
| 0 | 73 (100%) |
| 1 | 0 (0%) |
| Trastuzumab | |
| 0 | 71 (97%) |
| 1 | 2 (2.7%) |
| VEGF_TKI | |
| 0 | 71 (97%) |
| 1 | 2 (2.7%) |
| ICI_Class | |
| PD1 | 25 (34%) |
| Combination | 6 (8.2%) |
| CTLA4 | 40 (55%) |
| PDL1 | 2 (2.7%) |
| nephrotoxic_chemo | |
| 0 | 63 (86%) |
| 1 | 10 (14%) |
| pre_CRE_180days | 0.86 (0.78, 1.02) |
| pre_HGB_180days | 13.70 (12.60, 14.50) |
| pre_ALB_180days | 4.40 (4.20, 4.70) |
| eGFR_CRE_baseline | 91 (75, 101) |
| 1 Median (Q1, Q3); n (%) | |
CIF
CIF survival >365 days Event number : death + ckd composite
ckd_stage vs ckd_composite_1year
| 0 (N=8863) |
1 (N=325) |
Overall (N=9188) |
|
|---|---|---|---|
| ckd_stage_baseline | |||
| 1 | 4153 (46.9%) | 77 (23.7%) | 4230 (46.0%) |
| 2 | 3524 (39.8%) | 194 (59.7%) | 3718 (40.5%) |
| 3 | 1127 (12.7%) | 46 (14.2%) | 1173 (12.8%) |
| 4 | 58 (0.7%) | 7 (2.2%) | 65 (0.7%) |
| 5 | 1 (0.0%) | 1 (0.3%) | 2 (0.0%) |
| factor(ckd_stage_1year) | |||
| 1 | 3737 (42.2%) | 1 (0.3%) | 3738 (40.7%) |
| 2 | 3780 (42.6%) | 54 (16.6%) | 3834 (41.7%) |
| 3 | 1284 (14.5%) | 230 (70.8%) | 1514 (16.5%) |
| 4 | 59 (0.7%) | 34 (10.5%) | 93 (1.0%) |
| 5 | 3 (0.0%) | 6 (1.8%) | 9 (0.1%) |
ckd_stage vs ckd_composite_2year
| 0 (N=5449) |
1 (N=407) |
Overall (N=5856) |
|
|---|---|---|---|
| ckd_stage_baseline | |||
| 1 | 2559 (47.0%) | 103 (25.3%) | 2662 (45.5%) |
| 2 | 2198 (40.3%) | 241 (59.2%) | 2439 (41.6%) |
| 3 | 659 (12.1%) | 56 (13.8%) | 715 (12.2%) |
| 4 | 32 (0.6%) | 6 (1.5%) | 38 (0.6%) |
| 5 | 1 (0.0%) | 1 (0.2%) | 2 (0.0%) |
| factor(ckd_stage_2year) | |||
| 1 | 2166 (39.8%) | 2 (0.5%) | 2168 (37.0%) |
| 2 | 2523 (46.3%) | 93 (22.9%) | 2616 (44.7%) |
| 3 | 723 (13.3%) | 282 (69.3%) | 1005 (17.2%) |
| 4 | 37 (0.7%) | 24 (5.9%) | 61 (1.0%) |
| 5 | 0 (0%) | 6 (1.5%) | 6 (0.1%) |
ckd_stage vs ckd_composite_3year
| 0 (N=3309) |
1 (N=346) |
Overall (N=3655) |
|
|---|---|---|---|
| ckd_stage_baseline | |||
| 1 | 1585 (47.9%) | 93 (26.9%) | 1678 (45.9%) |
| 2 | 1331 (40.2%) | 194 (56.1%) | 1525 (41.7%) |
| 3 | 382 (11.5%) | 53 (15.3%) | 435 (11.9%) |
| 4 | 10 (0.3%) | 6 (1.7%) | 16 (0.4%) |
| 5 | 1 (0.0%) | 0 (0%) | 1 (0.0%) |
| factor(ckd_stage_3year) | |||
| 1 | 1281 (38.7%) | 8 (2.3%) | 1289 (35.3%) |
| 2 | 1610 (48.7%) | 101 (29.2%) | 1711 (46.8%) |
| 3 | 399 (12.1%) | 207 (59.8%) | 606 (16.6%) |
| 4 | 19 (0.6%) | 23 (6.6%) | 42 (1.1%) |
| 5 | 0 (0%) | 7 (2.0%) | 7 (0.2%) |
ckd_stage vs ckd_composite_4year
| 0 (N=2164) |
1 (N=272) |
Overall (N=2436) |
|
|---|---|---|---|
| ckd_stage_baseline | |||
| 1 | 1070 (49.4%) | 74 (27.2%) | 1144 (47.0%) |
| 2 | 851 (39.3%) | 154 (56.6%) | 1005 (41.3%) |
| 3 | 236 (10.9%) | 42 (15.4%) | 278 (11.4%) |
| 4 | 6 (0.3%) | 2 (0.7%) | 8 (0.3%) |
| 5 | 1 (0.0%) | 0 (0%) | 1 (0.0%) |
| factor(ckd_stage_4year) | |||
| 1 | 865 (40.0%) | 13 (4.8%) | 878 (36.0%) |
| 2 | 1041 (48.1%) | 71 (26.1%) | 1112 (45.6%) |
| 3 | 249 (11.5%) | 171 (62.9%) | 420 (17.2%) |
| 4 | 9 (0.4%) | 15 (5.5%) | 24 (1.0%) |
| 5 | 0 (0%) | 2 (0.7%) | 2 (0.1%) |
ckd_stage vs ckd_composite_5year
| 0 (N=1442) |
1 (N=219) |
Overall (N=1661) |
|
|---|---|---|---|
| ckd_stage_baseline | |||
| 1 | 742 (51.5%) | 59 (26.9%) | 801 (48.2%) |
| 2 | 561 (38.9%) | 119 (54.3%) | 680 (40.9%) |
| 3 | 135 (9.4%) | 39 (17.8%) | 174 (10.5%) |
| 4 | 4 (0.3%) | 2 (0.9%) | 6 (0.4%) |
| 5 | 0 (0%) | 0 (0%) | 0 (0%) |
| factor(ckd_stage_5year) | |||
| 1 | 602 (41.7%) | 9 (4.1%) | 611 (36.8%) |
| 2 | 687 (47.6%) | 80 (36.5%) | 767 (46.2%) |
| 3 | 148 (10.3%) | 115 (52.5%) | 263 (15.8%) |
| 4 | 5 (0.3%) | 12 (5.5%) | 17 (1.0%) |
| 5 | 0 (0%) | 3 (1.4%) | 3 (0.2%) |
landmark 1year
landmark 2year
landmark 3year
landmark 4year
landmark 5year
cox model outcome: death. Survival 5 year
| Characteristic | N | HR1 | 95% CI1 | p-value |
|---|---|---|---|---|
| year_10 | 1,661 | 1.03 | 0.99, 1.08 | 0.106 |
| male | 1,661 | |||
| 0 | — | — | ||
| 1 | 0.97 | 0.88, 1.08 | 0.587 | |
| Race | 1,661 | |||
| Asian | — | — | ||
| Black | 0.56 | 0.31, 1.01 | 0.054 | |
| Other/Unknown | 0.97 | 0.62, 1.52 | 0.902 | |
| White | 0.73 | 0.51, 1.05 | 0.090 | |
| dm | 1,661 | |||
| 0 | — | — | ||
| 1 | 0.95 | 0.80, 1.13 | 0.579 | |
| htn | 1,661 | |||
| 0 | — | — | ||
| 1 | 0.82 | 0.74, 0.91 | <0.001 | |
| cad | 1,661 | |||
| 0 | — | — | ||
| 1 | 1.17 | 1.02, 1.34 | 0.022 | |
| ace_arb | 1,661 | |||
| 0 | — | — | ||
| 1 | 0.94 | 0.85, 1.05 | 0.265 | |
| diu | 1,661 | |||
| 0 | — | — | ||
| 1 | 0.88 | 0.79, 0.97 | 0.012 | |
| ppi | 1,661 | |||
| 0 | — | — | ||
| 1 | 0.76 | 0.68, 0.86 | <0.001 | |
| steroids | 1,661 | |||
| 0 | — | — | ||
| 1 | 1.22 | 1.08, 1.37 | <0.001 | |
| smoking | 1,661 | |||
| 0 | — | — | ||
| 1 | 0.97 | 0.87, 1.07 | 0.543 | |
| ckd_stage_baseline | 1,661 | |||
| 1 | — | — | ||
| 2 | 1.07 | 0.96, 1.20 | 0.216 | |
| 3 | 0.89 | 0.74, 1.07 | 0.224 | |
| 4 | 2.63 | 1.18, 5.89 | 0.018 | |
| 5 | ||||
| ckd_stage_5year | 1,661 | |||
| 1 | — | — | ||
| 2 | 1.11 | 0.99, 1.24 | 0.073 | |
| 3 | 1.01 | 0.86, 1.19 | 0.870 | |
| 4 | 1.55 | 0.89, 2.68 | 0.121 | |
| 5 | 1.10 | 0.27, 4.40 | 0.896 | |
| Bevacizumab | 1,661 | |||
| 0 | — | — | ||
| 1 | 0.99 | 0.76, 1.29 | 0.956 | |
| Cisplatin | 1,661 | |||
| 0 | — | — | ||
| 1 | 1.35 | 1.13, 1.60 | <0.001 | |
| Carboplatin | 1,661 | |||
| 0 | — | — | ||
| 1 | 1.16 | 1.02, 1.33 | 0.030 | |
| Pemetrexed | 1,661 | |||
| 0 | — | — | ||
| 1 | 1.05 | 0.87, 1.26 | 0.616 | |
| Gemcitabine | 1,661 | |||
| 0 | — | — | ||
| 1 | 1.19 | 0.97, 1.46 | 0.101 | |
| Cetuximab | 1,661 | |||
| 0 | — | — | ||
| 1 | 1.12 | 0.63, 1.98 | 0.697 | |
| Trastuzumab | 1,661 | |||
| 0 | — | — | ||
| 1 | 0.94 | 0.64, 1.40 | 0.773 | |
| VEGF_TKI | 1,661 | |||
| 0 | — | — | ||
| 1 | 1.10 | 0.88, 1.37 | 0.424 | |
| ICI_Class | 1,661 | |||
| PD1 | — | — | ||
| Combination | 0.97 | 0.83, 1.13 | 0.668 | |
| CTLA4 | 0.28 | 0.23, 0.35 | <0.001 | |
| PDL1 | 1.07 | 0.91, 1.26 | 0.411 | |
| cancer_type | 1,661 | |||
| breast | — | — | ||
| cutaneous / melanoma | 0.59 | 0.44, 0.77 | <0.001 | |
| endocrine | ||||
| gi | 1.54 | 1.07, 2.20 | 0.019 | |
| gu | 1.00 | 0.74, 1.35 | 0.991 | |
| gyn | 1.19 | 0.81, 1.75 | 0.364 | |
| head and neck | 1.22 | 0.87, 1.70 | 0.246 | |
| heme | 0.68 | 0.49, 0.94 | 0.019 | |
| neuro | 1.35 | 0.84, 2.17 | 0.209 | |
| sarcoma | 2.50 | 1.24, 5.07 | 0.011 | |
| thoracic | 0.99 | 0.75, 1.32 | 0.963 | |
| eGFR_CRE_baseline_decrease_10 | 1,661 | 0.99 | 0.96, 1.02 | 0.377 |
| pre_CRE_180days | 1,661 | 0.90 | 0.73, 1.10 | 0.298 |
| ckd_composite_5year | 1,661 | |||
| 0 | — | — | ||
| 1 | 1.10 | 0.94, 1.29 | 0.242 | |
| 1 HR = Hazard Ratio, CI = Confidence Interval | ||||
logistic regression outcome: ckd_composite_5year
| Characteristic | N | OR1 | 95% CI1 | p-value |
|---|---|---|---|---|
| year_10 | 1,661 | 1.69 | 1.48, 1.94 | <0.001 |
| male | 1,661 | |||
| 0 | — | — | ||
| 1 | 0.74 | 0.56, 0.99 | 0.039 | |
| Race | 1,661 | |||
| Asian | — | — | ||
| Black | 2.61 | 0.66, 11.3 | 0.176 | |
| Other/Unknown | 0.78 | 0.19, 3.34 | 0.723 | |
| White | 1.26 | 0.49, 4.25 | 0.667 | |
| dm | 1,661 | |||
| 0 | — | — | ||
| 1 | 1.97 | 1.32, 2.88 | <0.001 | |
| htn | 1,661 | |||
| 0 | — | — | ||
| 1 | 1.86 | 1.37, 2.55 | <0.001 | |
| cad | 1,661 | |||
| 0 | — | — | ||
| 1 | 1.51 | 1.07, 2.10 | 0.017 | |
| ace_arb | 1,661 | |||
| 0 | — | — | ||
| 1 | 2.45 | 1.82, 3.31 | <0.001 | |
| diu | 1,661 | |||
| 0 | — | — | ||
| 1 | 2.91 | 2.13, 4.04 | <0.001 | |
| ppi | 1,661 | |||
| 0 | — | — | ||
| 1 | 1.79 | 1.24, 2.66 | 0.003 | |
| steroids | 1,661 | |||
| 0 | — | — | ||
| 1 | 0.86 | 0.63, 1.17 | 0.328 | |
| smoking | 1,661 | |||
| 0 | — | — | ||
| 1 | 1.66 | 1.24, 2.23 | <0.001 | |
| statins | 1,661 | 1.60 | 1.20, 2.16 | 0.002 |
| Bevacizumab | 1,661 | |||
| 0 | — | — | ||
| 1 | 1.69 | 0.91, 2.96 | 0.077 | |
| Cisplatin | 1,661 | |||
| 0 | — | — | ||
| 1 | 1.32 | 0.85, 2.00 | 0.196 | |
| Carboplatin | 1,661 | |||
| 0 | — | — | ||
| 1 | 1.55 | 1.11, 2.13 | 0.008 | |
| Pemetrexed | 1,661 | |||
| 0 | — | — | ||
| 1 | 1.62 | 1.05, 2.42 | 0.023 | |
| Gemcitabine | 1,661 | |||
| 0 | — | — | ||
| 1 | 1.52 | 0.94, 2.36 | 0.076 | |
| Cetuximab | 1,661 | |||
| 0 | — | — | ||
| 1 | 0.00 | 0.967 | ||
| Trastuzumab | 1,661 | |||
| 0 | — | — | ||
| 1 | 0.63 | 0.15, 1.79 | 0.451 | |
| VEGF_TKI | 1,661 | |||
| 0 | — | — | ||
| 1 | 1.57 | 0.92, 2.55 | 0.084 | |
| eGFR_CRE_5year_decrease_10 | 1,661 | 2.11 | 1.92, 2.33 | <0.001 |
| ICI_Class | 1,661 | |||
| PD1 | — | — | ||
| Combination | 0.94 | 0.58, 1.45 | 0.778 | |
| CTLA4 | 0.90 | 0.48, 1.56 | 0.722 | |
| PDL1 | 1.33 | 0.88, 1.98 | 0.165 | |
| cancer_type | 1,661 | |||
| breast | — | — | ||
| cutaneous / melanoma | 1.20 | 0.51, 3.54 | 0.707 | |
| gi | 3.15 | 1.15, 10.1 | 0.035 | |
| gu | 2.59 | 1.06, 7.77 | 0.057 | |
| gyn | 2.55 | 0.87, 8.56 | 0.102 | |
| head and neck | 1.38 | 0.48, 4.51 | 0.565 | |
| heme | 1.36 | 0.48, 4.46 | 0.577 | |
| neuro | 0.86 | 0.12, 4.27 | 0.861 | |
| sarcoma | 2.90 | 0.37, 16.2 | 0.246 | |
| thoracic | 2.42 | 1.02, 7.16 | 0.069 | |
| pre_CRE_180days | 1,661 | 2.50 | 1.59, 3.89 | <0.001 |
| 1 OR = Odds Ratio, CI = Confidence Interval | ||||
Fine & Grey model for all
## 87 cases omitted due to missing values| Characteristic | N | HR1 | 95% CI1 | p-value |
|---|---|---|---|---|
| year_10 | 17,718 | 1.52 | 1.44, 1.59 | <0.001 |
| male | 17,718 | |||
| 0 | — | — | ||
| 1 | 0.85 | 0.75, 0.97 | 0.015 | |
| Race | 17,718 | |||
| Asian | — | — | ||
| Black | 1.32 | 0.76, 2.27 | 0.320 | |
| Other/Unknown | 0.96 | 0.56, 1.64 | 0.880 | |
| White | 1.25 | 0.83, 1.88 | 0.280 | |
| dm | 17,718 | |||
| 0 | — | — | ||
| 1 | 1.81 | 1.55, 2.11 | <0.001 | |
| htn | 17,718 | |||
| 0 | — | — | ||
| 1 | 1.59 | 1.38, 1.82 | <0.001 | |
| cad | 17,718 | |||
| 0 | — | — | ||
| 1 | 1.41 | 1.22, 1.63 | <0.001 | |
| ace_arb | 17,718 | |||
| 0 | — | — | ||
| 1 | 1.93 | 1.69, 2.20 | <0.001 | |
| diu | 17,718 | |||
| 0 | — | — | ||
| 1 | 2.19 | 1.90, 2.52 | <0.001 | |
| ppi | 17,718 | |||
| 0 | — | — | ||
| 1 | 1.36 | 1.17, 1.59 | <0.001 | |
| steroids | 17,718 | |||
| 0 | — | — | ||
| 1 | 0.94 | 0.81, 1.08 | 0.360 | |
| smoking | 17,718 | |||
| 0 | — | — | ||
| 1 | 1.38 | 1.21, 1.57 | <0.001 | |
| statins | 17,718 | 1.68 | 1.48, 1.92 | <0.001 |
| Bevacizumab | 17,718 | |||
| 0 | — | — | ||
| 1 | 0.88 | 0.67, 1.17 | 0.380 | |
| Cisplatin | 17,718 | |||
| 0 | — | — | ||
| 1 | 1.06 | 0.88, 1.28 | 0.520 | |
| Carboplatin | 17,718 | |||
| 0 | — | — | ||
| 1 | 1.19 | 1.04, 1.36 | 0.013 | |
| Pemetrexed | 17,718 | |||
| 0 | — | — | ||
| 1 | 1.88 | 1.61, 2.20 | <0.001 | |
| Gemcitabine | 17,718 | |||
| 0 | — | — | ||
| 1 | 1.18 | 0.97, 1.42 | 0.093 | |
| Cetuximab | 17,718 | |||
| 0 | — | — | ||
| 1 | 0.48 | 0.26, 0.89 | 0.021 | |
| Trastuzumab | 17,718 | |||
| 0 | — | — | ||
| 1 | 0.76 | 0.49, 1.18 | 0.220 | |
| VEGF_TKI | 17,718 | |||
| 0 | — | — | ||
| 1 | 1.42 | 1.16, 1.74 | <0.001 | |
| eGFR_CRE_baseline | 17,718 | 0.98 | 0.98, 0.98 | <0.001 |
| ICI_Class | 17,631 | |||
| PD1 | — | — | ||
| Combination | 0.95 | 0.78, 1.16 | 0.650 | |
| CTLA4 | 0.95 | 0.71, 1.27 | 0.750 | |
| PDL1 | 1.07 | 0.89, 1.28 | 0.470 | |
| cancer_type | 17,718 | |||
| breast | — | — | ||
| cutaneous / melanoma | 1.35 | 0.93, 1.96 | 0.110 | |
| endocrine | 33.8 | 3.60, 317 | 0.002 | |
| gi | 2.25 | 1.54, 3.30 | <0.001 | |
| gu | 2.83 | 1.96, 4.08 | <0.001 | |
| gyn | 1.79 | 1.15, 2.80 | 0.010 | |
| head and neck | 1.14 | 0.72, 1.80 | 0.570 | |
| heme | 1.41 | 0.89, 2.21 | 0.140 | |
| neuro | 0.71 | 0.36, 1.41 | 0.330 | |
| sarcoma | 1.55 | 0.72, 3.31 | 0.260 | |
| thoracic | 2.61 | 1.83, 3.71 | <0.001 | |
| pre_CRE_180days | 17,718 | 2.29 | 1.99, 2.63 | <0.001 |
| 1 HR = Hazard Ratio, CI = Confidence Interval | ||||